文献速递胸部肿瘤放疗

综合二代测序揭示局限期小细胞肺癌放化疗后复发与胸部毒性风险的新型预测生物标志物

Comprehensive Next-Generation Sequencing Reveals Novel Predictive Biomarkers of Recurrence and Thoracic Toxicity Risks After Chemoradiation Therapy in Limited Stage Small Cell Lung Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-12-20

该研究对2015至2019年间接受根治性放化疗的231例局限期小细胞肺癌患者进行回顾性基因组分析,探索无进展生存、总生存和放射性胸部毒性与临床特征、肿瘤遗传学及单核苷酸多态性的关联,识别出CDK4、GATA6改变及高肿瘤突变负荷等生存预测因子和MTHFR、CYP2B6、NQO1、LIG4单核苷酸多态性及DNA损伤修复通路功能缺失突变等高级别放射性胸部毒性风险等位基因。

要点

  • CDK4和GATA6改变是多变量分析中生存不良的独立预测因子。
  • 高肿瘤突变负荷与有利生存结局强相关,MAPK/ERK通路激活突变(尤其EGFR/ERBB2)与生存不良相关。
  • MTHFR、CYP2B6、NQO1、LIG4单核苷酸多态性是高级别放射性胸部毒性的风险等位基因,DNA损伤修复通路功能缺失突变与高级别放射性胸部毒性(尤其肺炎)风险增加相关。

核心结论

  • 通过分析大样本局限期小细胞肺癌的突变图谱,识别出生存和放射性胸部毒性的新型分子预测因子。
  • 研究结果提示MAPK/ERK和DNA损伤修复通路参与调控根治性放化疗反应。

研究设计与样本

  • 回顾性基因组分析,纳入2015至2019年间接受根治性放化疗的231例局限期小细胞肺癌患者,使用覆盖癌症和放疗反应相关基因的定制面板进行测序。
  • 探索性分析无进展生存、总生存和放射性胸部毒性与临床特征、肿瘤遗传学、基因组和分子通路改变及单核苷酸多态性的关联。

主要发现

  • 除TP53、RB1和NOTCH1/2等常见小细胞肺癌基因外,EGFR、KRAS和BRCA1/2中潜在可靶向突变位于队列前列。
  • 单基因水平,CDK4和GATA6改变是多变量分析中生存不良的独立预测因子。
  • 基因组水平,高肿瘤突变负荷与有利生存结局强相关。
  • 通路水平分析显示MAPK/ERK通路基因激活突变(尤其EGFR/ERBB2)与生存不良相关,联合分析可实现根治性放化疗后生存的优化风险分层。
  • MTHFR、CYP2B6、NQO1和LIG4单核苷酸多态性被证实为高级别放射性胸部毒性的风险等位基因,DNA损伤修复通路基因体细胞功能缺失突变与高级别放射性胸部毒性(尤其肺炎)风险增加相关。

关键数值与推荐

  • CDK4和GATA6改变为生存不良的独立预测因子(多变量分析)。
  • 高肿瘤突变负荷与有利生存结局强相关。
  • MAPK/ERK通路基因激活突变(尤其EGFR/ERBB2)与生存不良相关。
  • MTHFR、CYP2B6、NQO1和LIG4单核苷酸多态性为高级别放射性胸部毒性的风险等位基因。
  • DNA损伤修复通路基因体细胞功能缺失突变与高级别放射性胸部毒性(尤其肺炎)风险增加相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although definitive chemoradiation therapy (dCRT) remains the most effective treatment modality in limited stage small cell lung cancer (SCLC), some patients progress quickly or develop serious radiation-induced thoracic toxicity (RITT). Molecular correlates of response to dCRT remain to be explored. METHODS AND MATERIALS: Genomic profiling was performed retrospectively on 231 patients with limited-stage SCLC treated with dCRT between 2015 and 2019 using a customized panel covering cancer and radiation therapy response-related genes. Exploratory associations of progression-free survival, overall survival, and RITT with clinical features, tumor genetics, genomic and molecular pathway alterations, and single nucleotide polymorphisms were conducted. RESULTS: In addition to the common SCLC genes, such as TP53, RB1, and NOTCH1/2, potentially actionable mutations in EGFR, KRAS, and BRCA1/2 were among the top alterations in the cohort. At the single-gene level, CDK4 and GATA6 alterations were independent predictors of poor survival by multivariate analysis. At the genomic level, high tumor mutational burden was strongly associated with favorable survival outcome. Pathway-level analysis showed that activating mutations in the MAPK/ERK pathway genes, particularly those in EGFR/ERBB2, correlated with poor survival. Combined analysis enabled optimized risk stratification of post-dCRT survival. On the other hand, our study also confirmed that single nucleotide polymorphisms in MTHFR, CYP2B6, NQO1, and LIG4 were risk alleles of high-grade RITT. Remarkably, somatic loss-of-function mutations in the DNA damage repair pathway genes were associated with increased risk of high-grade RITT, particularly pneumonitis, which likely reflect a complex interplay between the tumor and its immune microenvironment. CONCLUSIONS: Taken together, by examining the mutational landscape of a large cohort of limited-stage SCLC, we identified novel molecular predictors of survival and RITT. Our findings also implicate several key molecular pathways, including the MAPK/ERK and DNA damage repair pathways, in the regulation of dCRT response.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Li L, Tang S, Yin JC, et al. Comprehensive Next-Generation Sequencing Reveals Novel Predictive Biomarkers of Recurrence and Thoracic Toxicity Risks After Chemoradiation Therapy in Limited Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2021. PMID: 34942313. doi:10.1016/j.ijrobp.2021.12.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。